SCHEMBL1740342

SCHEMBL1740342

OC1(Cc2ccccc2)CNC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 2/20 0.46
OPRK1 P41145 2/20 0.46
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
GRIN2B Q13224 2/20 0.39
HSD11B1 P28845 1/20 0.39
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9938014 0.98 OPRL1 (0.49) OPRL1OPRK1OPRM1OPRD1MAOA
SCHEMBL16600810 0.84 GRIN2B (0.46) OPRL1OPRK1OPRM1OPRD1MAOA
SCHEMBL5509592 0.84 SLC6A2 (0.47) OPRL1OPRK1OPRM1OPRD1MAOA
Hydrochloric Acid SCHEMBL18038811 0.83 OPRL1 (0.47) OPRL1OPRK1OPRM1OPRD1MAOA
SCHEMBL20109496 0.81 CYP2D6 (0.46) OPRL1OPRK1OPRM1OPRD1MAOA
Tert-Butyl Formate SCHEMBL28821595 0.81 OPRL1 (0.38) OPRL1OPRK1OPRM1OPRD1SLC6A2
SCHEMBL23343753 0.79 OPRL1 (0.65) OPRL1OPRK1OPRM1OPRD1MAOA
SCHEMBL613290 0.79 OPRL1 (0.51) OPRL1OPRK1OPRM1OPRD1MAOA
SCHEMBL24362269 0.79 GRIN2D (0.41) OPRL1OPRK1OPRM1OPRD1GRIN2B
SCHEMBL27917951 0.79 ALDH1A1 (0.39) MAOAMAOBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113226356-B Activation of pyruvate kinase R 诺沃挪第克健康护理股份公司 2025-03-04 CN disclosed
US-12122778-B2 Activating pyruvate kinase R NOVO NORDISK HEALTH CARE AG (CH) 2024-10-22 US disclosed
EP-3852791-B1 ACTIVATING PYRUVATE KINASE R NOVO NORDISK HEALTHCARE AG (CH) 2024-07-03 EP disclosed
US-20240067631-A1 PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS CYTOKINETICS, INC. 2024-02-29 US disclosed
US-20230055923-A1 ACTIVATING PYRUVATE KINASE R NOVO NORDISK HEALTH CARE AG (CH) 2023-02-23 US disclosed
US-20230055923-A1 ACTIVATING PYRUVATE KINASE R NOVO NORDISK HEALTH CARE AG (CH) 2023-02-23 US disclosed
CN-113226356-A Activating pyruvate kinase R 福马治疗股份有限公司 2021-08-06 CN disclosed
EP-3852791-A1 ACTIVATING PYRUVATE KINASE R Forma Therapeutics, Inc. (US) 2021-07-28 EP disclosed
WO-2020061255-A1 ACTIVATING PYRUVATE KINASE R FORMA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed
WO-2020061255-A1 ACTIVATING PYRUVATE KINASE R FORMA THERAPEUTICS, INC. (US) 2020-03-26 WO disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 US disclosed
CN-102292340-A Amino-heterocyclic compounds used as PDE9 inhibitors 2011-12-21 CN disclosed
EP-2389382-A1 Amino-heterocyclic compounds used as pde9 inhibitors Pfizer Inc. (US) 2011-11-30 EP disclosed
US-8041687-B2 Dynamic generation of XML Schema for backend driven data validation INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2011-10-18 US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 US disclosed
WO-2010084438-A1 AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS PFIZER INC. (US) 2010-07-29 WO disclosed
WO-2010084438-A1 AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS PFIZER INC. (US) 2010-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055923-A1 ACTIVATING PYRUVATE KINASE R PDK1, PDK2, PKLR OPRL1 4439/4885OPRK1 2248/4885OPRM1 4484/4885
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A OPRL1 1769/4885OPRK1 1981/4885OPRM1 3328/4885
US-20240067631-A1 PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS NAMPT, NNT, NAPRT OPRL1 3059/4885OPRK1 3021/4885OPRM1 3418/4885
US-12122778-B2 Activating pyruvate kinase R PDK1, PDK2, PKLR OPRL1 4439/4885OPRK1 2248/4885OPRM1 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.